Uses of anti-Müllerian hormone (AMH) measurement before and after cancer treatment in women

Cheryl E Dunlop, Richard Anderson

Research output: Contribution to journalLiterature reviewpeer-review

Abstract

There is a growing body of evidence supporting the use of anti-Müllerian hormone (AMH) serum levels as a biomarker of the growing follicle pool, in turn taken to reflect the ovarian reserve, in patients being treated for cancer. Many cancer therapies are gonadotoxic, often inducing premature ovarian insufficiency (POI) and thus rendering such patients infertile. The degree of ovariotoxicity is related to the type of treatment, dosage and patient's age. As survival rates from cancer improve, post-treatment reproductive health is becoming increasingly important to affected girls and women of reproductive age to allow them to have biologically-related children. AMH levels taken post-treatment may be able to guide advice regarding remaining reproductive lifespan and aid decision-making on suitable adjuvant hormonal treatments such as in hormone receptor-positive breast cancer. Furthermore, pre-treatment AMH levels are now shown to be predictive of long-term ovarian function. The development of prognostic scoring and classification methods including the use of pre-treatment AMH, as well as other patient factors including age, to determine the likelihood of return of menses may allow better individualisation of advice regarding the use of fertility preservation strategies prior to commencing cancer treatment. AMH may also be a useful marker of cancer therapy-related ovarian damage in pre-pubertal children, although there are very limited data on the relationship between AMH and the ovarian reserve in children and adolescents. AMH is proving to be of increasing value in assessing ovarian function and advising patients before and after cancer treatment.

Original languageEnglish
Pages (from-to)245-250
Number of pages6
JournalMaturitas
Volume80
Issue number3
Early online date18 Dec 2014
DOIs
Publication statusPublished - Mar 2015

Keywords

  • Anti-Mullerian hormone
  • Cancer
  • Chemotherapy
  • Ovarian reserve
  • Premature ovarian insufficiency
  • CHEMOTHERAPY-RELATED AMENORRHEA
  • STAGE BREAST-CANCER
  • OVARIAN RESERVE
  • YOUNG-WOMEN
  • ANTIMULLERIAN HORMONE
  • CHILDHOOD-CANCER
  • PREMENOPAUSAL WOMEN
  • MLLERIAN HORMONE
  • FEMALE SURVIVORS
  • MOUSE OVARY

Fingerprint

Dive into the research topics of 'Uses of anti-Müllerian hormone (AMH) measurement before and after cancer treatment in women'. Together they form a unique fingerprint.

Cite this